APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral and Injectable Medications for Type 2 Diabetes

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral and Injectable Medications for Type 2 Diabetes Market Outlook and Growth Opportunities 2026

23 December 2025202 pages

Choose your research edition.

Industry ResearchOral and Injectable Medications for Type 2 Diabetes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral and Injectable Medications for Type 2 Diabetes Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Oral and Injectable Medications for Type 2 Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral and Injectable Medications for Type 2 Diabetes Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral and Injectable Medications for Type 2 Diabetes Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral and Injectable Medications for Type 2 Diabetes market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral and Injectable Medications for Type 2 Diabetes market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral and Injectable Medications for Type 2 Diabetes market include United Laboratories, Yiling Pharmaceutical, Takeda, Tonghua Dongbao, Sanofi, Novo Nordisk, Merck, Eli Lilly and Jiangsu Wanbang, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral and Injectable Medications for Type 2 Diabetes market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral and Injectable Medications for Type 2 Diabetes and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral and Injectable Medications for Type 2 Diabetes sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral and Injectable Medications for Type 2 Diabetes market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral and Injectable Medications for Type 2 Diabetes Segment by Company

United Laboratories

Yiling Pharmaceutical

Takeda

Tonghua Dongbao

Sanofi

Novo Nordisk

Merck

Eli Lilly

Jiangsu Wanbang

Jiangsu Hengrui Pharmaceuticals

Pfizer

Beijing Double-Crane Pharmaceutical

Huadong Medicine

Ganli Pharmaceutical

Beijing Beilu Pharmaceutical

bayer

AstraZeneca

Boehringer Ingelheim

Biocon

Oral and Injectable Medications for Type 2 Diabetes Segment by Type

Insulin

Biguanides

Sulfonylureas

SGLT2 Inhibitors

GLP‑1 Receptor Agonists

DPP‑4 Inhibitors

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Application

Clinic

Hospital

Pharmacy

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oral and Injectable Medications for Type 2 Diabetes status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oral and Injectable Medications for Type 2 Diabetes market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral and Injectable Medications for Type 2 Diabetes significant trends, drivers, influence factors in global and regions.

6. To analyze Oral and Injectable Medications for Type 2 Diabetes competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral and Injectable Medications for Type 2 Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral and Injectable Medications for Type 2 Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral and Injectable Medications for Type 2 Diabetes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral and Injectable Medications for Type 2 Diabetes market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral and Injectable Medications for Type 2 Diabetes industry.

Chapter 3: Detailed analysis of Oral and Injectable Medications for Type 2 Diabetes manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oral and Injectable Medications for Type 2 Diabetes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oral and Injectable Medications for Type 2 Diabetes in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral and Injectable Medications for Type 2 Diabetes Industry Trends Table 2. Oral and Injectable Medications for Type 2 Diabetes Industry Drivers Table 3. Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges Table 4. Oral and Injectable Medications for Type 2 Diabetes Industry Restraints Table 5. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Company (2021-2026) Table 7. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Company (k units) & (2021-2026) Table 8. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Company (2021-2026) Table 9. Global Oral and Injectable Medications for Type 2 Diabetes Average Price (USD/unit) of Company (2021-2026) Table 10. Global Oral and Injectable Medications for Type 2 Diabetes Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oral and Injectable Medications for Type 2 Diabetes Key Company Manufacturing Base & Headquarters Table 12. Global Oral and Injectable Medications for Type 2 Diabetes Company, Product Type & Application Table 13. Global Oral and Injectable Medications for Type 2 Diabetes Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral and Injectable Medications for Type 2 Diabetes by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Insulin Table 18. Significant Companies of Biguanides Table 19. Significant Companies of Sulfonylureas Table 20. Significant Companies of SGLT2 Inhibitors Table 21. Significant Companies of GLP‑1 Receptor Agonists Table 22. Significant Companies of DPP‑4 Inhibitors Table 23. Significant Companies of Others Table 24. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type (2021-2026) & (k units) Table 26. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type (2027-2032) & (k units) Table 27. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Type (2021-2026) Table 28. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Type (2027-2032) Table 29. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type (2021-2026) Table 33. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Clinic Table 35. Significant Companies of Hospital Table 36. Significant Companies of Pharmacy Table 37. Significant Companies of Others Table 38. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application (2021-2026) & (k units) Table 40. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application (2027-2032) & (k units) Table 41. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Application (2021-2026) Table 42. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Application (2027-2032) Table 43. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application (2021-2026) Table 47. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application (2027-2032) Table 48. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 49. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026) & (k units) Table 50. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2021-2026) Table 51. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032) & (k units) Table 52. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2027-2032) Table 53. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Region (2021-2026) Table 56. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Region (2027-2032) Table 58. Global Oral and Injectable Medications for Type 2 Diabetes Market Average Price (USD/unit) by Region (2021-2026) Table 59. Global Oral and Injectable Medications for Type 2 Diabetes Market Average Price (USD/unit) by Region (2027-2032) Table 60. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 61. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 63. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2026) Table 64. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 65. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2027-2032) Table 66. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Market Share by Country (2021-2026) Table 68. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Market Share by Country (2027-2032) Table 70. United Laboratories Company Information Table 71. United Laboratories Business Overview Table 72. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 74. United Laboratories Recent Development Table 75. Yiling Pharmaceutical Company Information Table 76. Yiling Pharmaceutical Business Overview Table 77. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 79. Yiling Pharmaceutical Recent Development Table 80. Takeda Company Information Table 81. Takeda Business Overview Table 82. Takeda Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 84. Takeda Recent Development Table 85. Tonghua Dongbao Company Information Table 86. Tonghua Dongbao Business Overview Table 87. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 89. Tonghua Dongbao Recent Development Table 90. Sanofi Company Information Table 91. Sanofi Business Overview Table 92. Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 94. Sanofi Recent Development Table 95. Novo Nordisk Company Information Table 96. Novo Nordisk Business Overview Table 97. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 99. Novo Nordisk Recent Development Table 100. Merck Company Information Table 101. Merck Business Overview Table 102. Merck Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 104. Merck Recent Development Table 105. Eli Lilly Company Information Table 106. Eli Lilly Business Overview Table 107. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 109. Eli Lilly Recent Development Table 110. Jiangsu Wanbang Company Information Table 111. Jiangsu Wanbang Business Overview Table 112. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 114. Jiangsu Wanbang Recent Development Table 115. Jiangsu Hengrui Pharmaceuticals Company Information Table 116. Jiangsu Hengrui Pharmaceuticals Business Overview Table 117. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 119. Jiangsu Hengrui Pharmaceuticals Recent Development Table 120. Pfizer Company Information Table 121. Pfizer Business Overview Table 122. Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 124. Pfizer Recent Development Table 125. Beijing Double-Crane Pharmaceutical Company Information Table 126. Beijing Double-Crane Pharmaceutical Business Overview Table 127. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 129. Beijing Double-Crane Pharmaceutical Recent Development Table 130. Huadong Medicine Company Information Table 131. Huadong Medicine Business Overview Table 132. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 134. Huadong Medicine Recent Development Table 135. Ganli Pharmaceutical Company Information Table 136. Ganli Pharmaceutical Business Overview Table 137. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 139. Ganli Pharmaceutical Recent Development Table 140. Beijing Beilu Pharmaceutical Company Information Table 141. Beijing Beilu Pharmaceutical Business Overview Table 142. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 144. Beijing Beilu Pharmaceutical Recent Development Table 145. bayer Company Information Table 146. bayer Business Overview Table 147. bayer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 148. bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 149. bayer Recent Development Table 150. AstraZeneca Company Information Table 151. AstraZeneca Business Overview Table 152. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 153. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 154. AstraZeneca Recent Development Table 155. Boehringer Ingelheim Company Information Table 156. Boehringer Ingelheim Business Overview Table 157. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 158. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 159. Boehringer Ingelheim Recent Development Table 160. Biocon Company Information Table 161. Biocon Business Overview Table 162. Biocon Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 163. Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 164. Biocon Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Oral and Injectable Medications for Type 2 Diabetes Distributors List Table 168. Oral and Injectable Medications for Type 2 Diabetes Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Oral and Injectable Medications for Type 2 Diabetes Product Image Figure 2. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2032) & (k units) Figure 5. Global Oral and Injectable Medications for Type 2 Diabetes Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Oral and Injectable Medications for Type 2 Diabetes Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Insulin Image Figure 10. Biguanides Image Figure 11. Sulfonylureas Image Figure 12. SGLT2 Inhibitors Image Figure 13. GLP‑1 Receptor Agonists Image Figure 14. DPP‑4 Inhibitors Image Figure 15. Others Image Figure 16. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Type (2021-2032) Figure 19. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. Pharmacy Image Figure 25. Others Image Figure 26. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Application (2021-2032) Figure 29. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application (2021-2032) Figure 32. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 33. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032) & (US$ Million) Figure 37. North America Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032) & (US$ Million) Figure 43. South America Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Oral and Injectable Medications for Type 2 Diabetes Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Oral and Injectable Medications for Type 2 Diabetes Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin
  • Biguanides
  • Sulfonylureas
  • SGLT2 Inhibitors
  • GLP‑1 Receptor Agonists
  • DPP‑4 Inhibitors
  • Others
Applications
  • Clinic
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • United Laboratories
  • Yiling Pharmaceutical
  • Takeda
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Jiangsu Wanbang
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • Beijing Double-Crane Pharmaceutical
  • Huadong Medicine
  • Ganli Pharmaceutical
  • Beijing Beilu Pharmaceutical
  • bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032)
  4. 1.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume (2021-2032)
  5. 1.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oral and Injectable Medications for Type 2 Diabetes Market Dynamics
  1. 2.1 Oral and Injectable Medications for Type 2 Diabetes Industry Trends
  2. 2.2 Oral and Injectable Medications for Type 2 Diabetes Industry Drivers
  3. 2.3 Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges
  4. 2.4 Oral and Injectable Medications for Type 2 Diabetes Industry Restraints
3 Oral and Injectable Medications for Type 2 Diabetes Market by Company
  1. 3.1 Global Oral and Injectable Medications for Type 2 Diabetes Company Revenue Ranking in 2025
  2. 3.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Company (2021-2026)
  3. 3.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Company (2021-2026)
  4. 3.4 Global Oral and Injectable Medications for Type 2 Diabetes Average Price by Company (2021-2026)
  5. 3.5 Global Oral and Injectable Medications for Type 2 Diabetes Company Ranking (2024-2026)
  6. 3.6 Global Oral and Injectable Medications for Type 2 Diabetes Company Manufacturing Base and Headquarters
  7. 3.7 Global Oral and Injectable Medications for Type 2 Diabetes Company Product Type and Application
  8. 3.8 Global Oral and Injectable Medications for Type 2 Diabetes Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oral and Injectable Medications for Type 2 Diabetes Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oral and Injectable Medications for Type 2 Diabetes Market by Type
  1. 4.1 Oral and Injectable Medications for Type 2 Diabetes Type Introduction
  2. 4.1.1 Insulin
  3. 4.1.2 Biguanides
  4. 4.1.3 Sulfonylureas
  5. 4.1.4 SGLT2 Inhibitors
  6. 4.1.5 GLP‑1 Receptor Agonists
  7. 4.1.6 DPP‑4 Inhibitors
  8. 4.1.7 Others
  9. 4.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type
  10. 4.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type
  14. 4.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Type (2021-2032)
  16. 4.3.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type (2021-2032)
5 Oral and Injectable Medications for Type 2 Diabetes Market by Application
  1. 5.1 Oral and Injectable Medications for Type 2 Diabetes Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Pharmacy
  5. 5.1.4 Others
  6. 5.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application
  7. 5.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application
  11. 5.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Application (2021-2032)
  13. 5.3.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application (2021-2032)
6 Oral and Injectable Medications for Type 2 Diabetes Regional Sales and Value Analysis
  1. 6.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2032)
  3. 6.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021-2026
  4. 6.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032)
  5. 6.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Region (2027-2032)
  9. 6.5 Global Oral and Injectable Medications for Type 2 Diabetes Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032)
  12. 6.6.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032)
  15. 6.7.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032)
  21. 6.9.2 South America Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oral and Injectable Medications for Type 2 Diabetes Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Country, 2025 VS 2032
7 Oral and Injectable Medications for Type 2 Diabetes Country-level Sales and Value Analysis
  1. 7.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  4. 7.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026)
  5. 7.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032)
  6. 7.4 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oral and Injectable Medications for Type 2 Diabetes Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oral and Injectable Medications for Type 2 Diabetes Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 United Laboratories
  2. 8.1.1 United Laboratories Company Information
  3. 8.1.2 United Laboratories Business Overview
  4. 8.1.3 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  6. 8.1.5 United Laboratories Recent Developments
  7. 8.2 Yiling Pharmaceutical
  8. 8.2.1 Yiling Pharmaceutical Company Information
  9. 8.2.2 Yiling Pharmaceutical Business Overview
  10. 8.2.3 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  12. 8.2.5 Yiling Pharmaceutical Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Tonghua Dongbao
  20. 8.4.1 Tonghua Dongbao Company Information
  21. 8.4.2 Tonghua Dongbao Business Overview
  22. 8.4.3 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  24. 8.4.5 Tonghua Dongbao Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Jiangsu Wanbang
  50. 8.9.1 Jiangsu Wanbang Company Information
  51. 8.9.2 Jiangsu Wanbang Business Overview
  52. 8.9.3 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  54. 8.9.5 Jiangsu Wanbang Recent Developments
  55. 8.10 Jiangsu Hengrui Pharmaceuticals
  56. 8.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 8.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 8.10.3 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Beijing Double-Crane Pharmaceutical
  68. 8.12.1 Beijing Double-Crane Pharmaceutical Company Information
  69. 8.12.2 Beijing Double-Crane Pharmaceutical Business Overview
  70. 8.12.3 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  72. 8.12.5 Beijing Double-Crane Pharmaceutical Recent Developments
  73. 8.13 Huadong Medicine
  74. 8.13.1 Huadong Medicine Company Information
  75. 8.13.2 Huadong Medicine Business Overview
  76. 8.13.3 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  78. 8.13.5 Huadong Medicine Recent Developments
  79. 8.14 Ganli Pharmaceutical
  80. 8.14.1 Ganli Pharmaceutical Company Information
  81. 8.14.2 Ganli Pharmaceutical Business Overview
  82. 8.14.3 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  84. 8.14.5 Ganli Pharmaceutical Recent Developments
  85. 8.15 Beijing Beilu Pharmaceutical
  86. 8.15.1 Beijing Beilu Pharmaceutical Company Information
  87. 8.15.2 Beijing Beilu Pharmaceutical Business Overview
  88. 8.15.3 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  90. 8.15.5 Beijing Beilu Pharmaceutical Recent Developments
  91. 8.16 bayer
  92. 8.16.1 bayer Company Information
  93. 8.16.2 bayer Business Overview
  94. 8.16.3 bayer Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  96. 8.16.5 bayer Recent Developments
  97. 8.17 AstraZeneca
  98. 8.17.1 AstraZeneca Company Information
  99. 8.17.2 AstraZeneca Business Overview
  100. 8.17.3 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  102. 8.17.5 AstraZeneca Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Biocon
  110. 8.19.1 Biocon Company Information
  111. 8.19.2 Biocon Business Overview
  112. 8.19.3 Biocon Oral and Injectable Medications for Type 2 Diabetes Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  114. 8.19.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral and Injectable Medications for Type 2 Diabetes Value Chain Analysis
  2. 9.1.1 Oral and Injectable Medications for Type 2 Diabetes Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral and Injectable Medications for Type 2 Diabetes Sales Mode & Process
  6. 9.2 Oral and Injectable Medications for Type 2 Diabetes Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral and Injectable Medications for Type 2 Diabetes Distributors
  9. 9.2.3 Oral and Injectable Medications for Type 2 Diabetes Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst